IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 589.85, up by 1.20 points or 0.20% from its previous closing of Rs. 588.65 on the BSE.

The scrip opened at Rs. 586.60 and has touched a high and low of Rs. 600.00 and Rs. 584.10 respectively. So far 1917 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022.

Last one week high and low of the scrip stood at Rs. 607.95 and Rs. 568.00 respectively. The current market cap of the company is Rs. 11743.66 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 17.87% and 12.52% respectively.

Alembic Pharmaceuticals has received PAS (Prior Approval Supplement) approval from the US Food & Drug Administration (USFDA) for its Supplemental Abbreviated New Drug Application (sANDA) Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.

The sANDA, submitted as ;Prior Approval Supplement’, provides for an alternate drug product manufacturing site - Alembic Pharmaceuticals, Formulation Division IV, Jarod, Gujarat, India for previously approved ANDA from Panelav Facility (F-I). This is the first product approval from Jarod Facility which was inspected in Dec 2022. The approved sANDA is therapeutically equivalent to the reference listed drug product (RLD), Lyrica Capsules, of Upjohn. Pregabalin Capsules are indicated for neuropathic pain, postherpetic neuralgia, and other indications.

Pregabalin Capsules have an estimated market size of $ 244 million for twelve months ending Sep 2022 according to IQVIA. Alembic has a cumulative total of 178 ANDA approvals (155 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.